Overview

Study of the Safety and Efficacy of FerrlecitĀ® Maintenance Dosing in Pediatric Hemodialysis Patients

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
A phase 4 clinical investigation in iron-replete pediatric hemodialysis patients, whose legal guardian had provided signed informed consent, and who had satisfied the inclusion and exclusion criteria of the study.
Phase:
Phase 4
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Ferric Compounds
Ferric gluconate